Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Slowing Down Stock
876.7000 -10.95 (-1.23%)
NSE Jan 13, 2026 15:31 PM
Volume: 50,280
 

logo
Alivus Life Sciences Ltd.
29 Apr 2023
876.70
-1.23%
buy
by BOB Capital Markets Ltd.
Target: 600
BOB Capital Markets Ltd.
Q4 revenue of Rs 6.2bn (+21% YoY) beat our estimate by 14% driven by recovery in CDMO and growth in API
 
Alivus Life Sciences.. has an average target of 1248.50 from 2 brokers.
More from Alivus Life Sciences Ltd.
Recommended
Market closes lower, dragged down by foreign investor outflows and mixed earnings
Trendlyne Marketwatch | 13 Jan 2026, 04:07PM
IPO wave continues as Amagi Media and Five SMEs open for subscription
| 12 Jan 2026, 06:40PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
| 27 Jul 2021